{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-020389","form_type":"8-K","ticker":"TXMD","cik":"0000025743","company_name":"TherapeuticsMD, Inc.","filed_at":"2022-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.097555+00:00","generated_at":"2026-06-25T15:44:58.038676+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"TherapeuticsMD Q1 net loss $49M on flat revenue; completes $150M vitaCare sale","bullets":["Total net product revenue $19.3M, down slightly from $19.6M Q1 2021.","Net loss $49.0M ($5.69 per share) vs $39.4M loss year ago; includes $8.4M debt extinguishment loss.","Cash $30.4M at March 31, down from $65.1M Dec 2021; used $120M vitaCare proceeds to reduce debt.","ANNOVERA prescriptions up 27% YoY to 8,014; new prescribers up 16% YoY.","Completed $150M divestiture of vitaCare in five weeks; $16M PIK fee waived."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-020389","json":"https://secwatch.observer/filing/0001564590-22-020389.json","markdown":"https://secwatch.observer/filing/0001564590-22-020389.md","text":"https://secwatch.observer/filing/0001564590-22-020389.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/25743/000156459022020389/0001564590-22-020389-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/25743/000156459022020389/txmd-8k_20220516.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T15:44:58.038676+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}